Welcome to the new morningstar.co.uk! Learn more about the changes and how our new features help your investing success.

Glaxo US Pharma Head To Leave Role, Poaches Merck KGaA Oncology Head

(Alliance News) - GlaxoSmithKline PLC said on Monday that the head of its US pharmaceuticals ...

Alliance News 12 August, 2019 | 5:00PM
Email Form

(Alliance News) - GlaxoSmithKline PLC said on Monday that the head of its US pharmaceuticals division Jack Bailey will step down at the end of the year and will be replaced by Merck KGaA's Maya Martinez-Davis.

Martinez-Davis will join the company in September before assuming the role of US pharmaceuticals head in January and Bailey will remain with the company as a strategic consultant through 2020.

Glaxo said Martinez-Davis is currently the Merck's head of global oncology in the Latin America region and spent 13 years at Pfizer Inc.

Global Pharmaceuticals President Luke Miels said: "As we continue to grow and reshape our business globally, we are pleased to have found a leader in Martinez-Davis who will bring a valuable US experience a deep therapy area expertise to expanding our speciality care capabilities."

Frankfurt-listed Merck, although historically related, is independent to US pharmaceutical firm Merck & Co.

Shares in Glaxo closed 0.1% lower at 1,667.54 pence each in London on Monday.

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
GlaxoSmithKline PLC 1,644.60 GBX 1.07

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites